Health-Related Quality of Life in the Phase III ASCENT Trial of Sacituzumab Govitecan Versus Standard Chemotherapy in Metastatic Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab govitecan prolongs progression-free survival and overall survival in patients with refractory/relapsed metastatic triple-negative breast cancer (mTNBC). Here, the authors investigated its effect on health-related quality of life (HRQoL) and found that sacituzumab govitecan maintained or improved HRQoL in patients with refractory or relapsed mTNBC despite worse diarrhea and a trend toward worse nausea/vomiting.